Companies
Companies
Carthera Raises €42m to Launch Clinical Trials
📢 Sorbonne University spin-out Carthera SA has closed its Series B funding round at €42m to launch clinical trials. The funds will be used to launch a registrational trial of its ultrasound-based medical device SonoCloud to treat recurrent glioblastoma. Carthera also plans to expand its pipeline in neurodegenerative diseases.
Massive Lyme Vaccine Trial Concludes with Promising Results
📢 Pfizer and Valneva's Phase 3 VALOR trial for Lyme vaccine, VLA15, completes enrollment with over 9,000 participants. 🌍🩺🔬😷
Revolutionary Gene-Editing Breakthrough: $30m Funding Secured
📰 Eligo Bioscience secures $30m for gene-editing solutions, targeting moderate to severe acne vulgaris and chronic diseases. 💰💉
Former AZ Plant Transformed into Resilience: Thriving in Colorado!
📰 Former AstraZeneca site in Boulder, Colorado transformed into Resilience, a multi-product facility offering flexible process development and more! 💪🏭🔬
Big Shake-Ups in CDMOs: Industry Leaders Revamp
📰 "Ins and Outs: High level changes at CDMOs" discusses recent leadership shifts in the competitive biotech industry. 🔍😯🌍💼⚙️💪📈👥
China Dominates Global Biotech Industry with ADC Partnerships
"📰 China rides high on the ADC partnership wave, capitalizing on global biotech collaborations for biopharmaceutical success. 🚀🌍🧪💼"
Abselion benchtop tech emerges victorious from UK’s dragon’s den
📰 Abselion benchtop tech emerges victorious from UK’s dragon’s den. Abselion, a benchtop small molecule reaction screening technology, has secured £550k funding on the BBC show. The technology can be used in various industries including pharmaceuticals, agrochemistry, and materials science. The funding will help in scaling up the technology for industrial use. 👨🔬💡
Oxford Biomedica acquires ABL Europe
📰 Oxford Biomedica has acquired ABL Europe, a CDMO specializing in viral vector manufacturing. 🤝 This acquisition will enable Oxford Biomedica to expand its manufacturing capabilities and meet the growing demand for gene and cell therapies. 💼 The deal will also enhance Oxford Biomedica's position as a leading player in the biotech industry. 💪🌍
Kymriah GMP issues in NJ led to FDA letter for Novartis
📰 The FDA has issued a warning letter to Novartis regarding manufacturing issues with their immunotherapy drug Kymriah. 👩⚕️ The letter highlights concerns with the company's quality control procedures and the potential risks to patient safety. 🏭 The issues were identified at a New Jersey facility that produces the therapy. 💊 Novartis has stated that they are working to address the FDA's concerns and ensure the quality and reliability of Kymriah.
Novartis invests $85m in China radioligand facility
🏢 Novartis is investing $85 million in a radioligand facility in China. 🇨🇳 This facility will develop radioligands for Novartis' targeted radiotherapy pipeline. 🏥 The investment reflects Novartis' commitment to expanding its presence in China and developing innovative therapies for patients. 💪 This investment is part of Novartis' strategy to advance precision medicine and address the unmet medical needs of patients. 🧬
